QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and ...
EIB is providing up to €37.5 million in venture debt to Xeltis as part of a new €50 million financing package that will help bring aXess, the company’s regenerative vascular access conduit, to market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback